MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.160
-0.070
-1.65%
After Hours: 4.270 +0.11 +2.64% 19:29 03/05 EST
OPEN
4.250
PREV CLOSE
4.230
HIGH
4.300
LOW
3.720
VOLUME
745.63K
TURNOVER
--
52 WEEK HIGH
6.14
52 WEEK LOW
0.8130
MARKET CAP
175.79M
P/E (TTM)
-1.4874
1D
5D
1M
3M
1Y
5Y
--Analyst Actions: Wedbush Adjusts Price Target on Idera Pharmaceuticals to $8 From $5 on Potential Financings, Keeps Outperform Rating
MT Newswires · 3d ago
BRIEF-Idera Pharmaceuticals Files For Shelf Of Up To 4.1 Mln Shares By Selling Stockholders
reuters.com · 4d ago
Robert W. Baird Maintains a Buy Rating on Idera (IDRA)
SmarterAnalyst · 5d ago
H.C. Wainwright Keeps a Buy Rating on Idera (IDRA)
In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Idera (IDRA), with a price target of $9.00. The company's shares
SmarterAnalyst · 5d ago
BRIEF-Idera Pharmaceuticals Posts Q4 Loss Per Share $2.11
reuters.com · 5d ago
8-K: IDERA PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- 0000861838 false 0000861838 2021-03-01 2021-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
Idera Pharmaceuticals EPS misses by $1.88
Idera Pharmaceuticals (IDRA): Q4 GAAP EPS of -$2.11 misses by $1.88.Cash, cash equivalents, and short-term investments of $37.7M.Press Release
Seekingalpha · 5d ago
Idera Pharmaceuticals 4Q R&D Expenses Total $5.1M >IDRA
Idera Pharmaceuticals 4Q R&D Expenses Total $5.1M >IDRA
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDRA. Analyze the recent business situations of Idera Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDRA stock price target is 8.33 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 12.09M
% Owned: 28.61%
Shares Outstanding: 42.26M
TypeInstitutionsShares
Increased
15
340.48K
New
17
918.48K
Decreased
11
549.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
James Geraghty
Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Vincent Milano
Chief Financial Officer/Senior Vice President
John Kirby
Chief Operating Officer/Senior Vice President
Daniel Soland
Senior Vice President/General Counsel/Secretary
Bryant Lim
Senior Vice President
Elizabeth Tarka
Independent Director
Cristina Csimma
Independent Director
Michael Dougherty
Independent Director
Mark Goldberg
Independent Director
Maxine Gowen
Independent Director
Carol Schafer
No Data
  • All
  • Financials
  • Insiders
More
About IDRA
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.